2.1804
price down icon3.09%   -0.0696
after-market アフターアワーズ: 2.18 -0.0004 -0.02%
loading
前日終値:
$2.25
開ける:
$2.24
24時間の取引高:
108.06K
Relative Volume:
0.56
時価総額:
$25.97M
収益:
-
当期純損益:
$-3.15M
株価収益率:
-7.1442
EPS:
-0.3052
ネットキャッシュフロー:
$-2.23M
1週間 パフォーマンス:
-18.03%
1か月 パフォーマンス:
-22.13%
6か月 パフォーマンス:
+38.88%
1年 パフォーマンス:
+0.48%
1日の値動き範囲:
Value
$1.9759
$2.56
1週間の範囲:
Value
$1.9759
$2.63
52週間の値動き範囲:
Value
$1.20
$4.0499

Cytomed Therapeutics Ltd Stock (GDTC) Company Profile

Name
名前
Cytomed Therapeutics Ltd
Name
セクター
Healthcare (1164)
Name
電話
-
Name
住所
-
Name
職員
0
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
GDTC's Discussions on Twitter

GDTC を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
GDTC
Cytomed Therapeutics Ltd
2.1804 25.97M 0 -3.15M -2.23M -0.3052
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Cytomed Therapeutics Ltd (GDTC) 最新ニュース

pulisher
Feb 27, 2025

CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 06, 2025

CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders - Marketscreener.com

Feb 06, 2025
pulisher
Jan 09, 2025

SunAct Cancer Institute and CytoMed begin phase 2 trials for Gamma Delta T-cell therapy - Express Healthcare

Jan 09, 2025
pulisher
Jan 08, 2025

CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 13.7% – Here’s What Happened - Defense World

Jan 08, 2025
pulisher
Jan 07, 2025

CytoMed and SunAct Collaborate on Cancer Immunotherapy Trials in India - Yahoo Finance

Jan 07, 2025
pulisher
Jan 07, 2025

CytoMed Therapeutics and SunAct to conduct solid tumour treatment trial in India - Yahoo Finance

Jan 07, 2025
pulisher
Jan 06, 2025

Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor - Benzinga

Jan 06, 2025
pulisher
Jan 06, 2025

CytoMed Therapeutics Limited Signs Business & Research Collaboration Agreement with Sunact Cancer Institute Private Limited to Advance Use of Allogeneic Off-The-Shelf Gamma Delta T Cells for Treatment of Solid Cancers in Proposed Phase 2 Clinical Tr - Marketscreener.com

Jan 06, 2025
pulisher
Jan 06, 2025

CytoMed and SunAct partner for cancer immunotherapy trials - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in - Marketscreener.com

Jan 06, 2025
pulisher
Jan 06, 2025

CytoMed Partners with SunAct for Groundbreaking Cancer Cell Therapy Trial in India - Stock Titan

Jan 06, 2025
pulisher
Jan 03, 2025

CytoMed Therapeutics Leads 3 US Penny Stocks To Consider - Simply Wall St

Jan 03, 2025
pulisher
Dec 11, 2024

CytoMed Therapeutics Limited Announces Resignation of Dr Tan Wee Kiat as Co-Chief Executive Officer, Effective December 31, 2024 - Marketscreener.com

Dec 11, 2024
pulisher
Dec 10, 2024

CytoMed Therapeutics Limited Announces Resignation of Dr Tan Wee Kiat as Director and Chief Operating Officer, Effective December 31, 2024 - Marketscreener.com

Dec 10, 2024
pulisher
Dec 05, 2024

CytoMed Therapeutics : Organisation and personnel changes Form 6 K - Marketscreener.com

Dec 05, 2024
pulisher
Dec 05, 2024

CytoMed Therapeutics And 2 Other US Penny Stocks To Watch - Simply Wall St

Dec 05, 2024
pulisher
Nov 20, 2024

CytoMed Therapeutics : Update on Clinical Milestone CytoMed Therapeutics Announces First Patient Dosed in its First in Human Phase I Clinical Trial of Allogeneic CAR Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematologica - Marketscreener.com

Nov 20, 2024
pulisher
Nov 20, 2024

CytoMed Therapeutics Limited Announces First Patient Dosed in Its First-In-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Marketscreener.com

Nov 20, 2024
pulisher
Nov 20, 2024

Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - GlobeNewswire

Nov 20, 2024
pulisher
Oct 23, 2024

Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Simply Wall St

Oct 23, 2024
pulisher
Oct 17, 2024

Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch

Oct 17, 2024
pulisher
Oct 16, 2024

Osteopore Partners with CytoMed in Regenerative Medicine - TipRanks

Oct 16, 2024
pulisher
Oct 08, 2024

CytoMed begins clinical trial for innovative cancer therapy - Investing.com

Oct 08, 2024
pulisher
Oct 07, 2024

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank - Marketscreener.com

Oct 07, 2024
pulisher
Oct 07, 2024

Cytomed Therapeutics announces NMRC co-funding support for ANGELICA trial - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

CytoMed Launches Innovative CAR-T Cell Trial - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

CytoMed begins clinical trial for innovative cancer therapy By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

CytoMed Therapeutics’ first-in-human Phase I ANGELICA - GlobeNewswire

Oct 07, 2024
pulisher
Oct 07, 2024

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant - StockTitan

Oct 07, 2024
pulisher
Oct 04, 2024

CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine - Yahoo Finance

Oct 04, 2024
pulisher
Oct 03, 2024

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank - The Manila Times

Oct 03, 2024
pulisher
Oct 03, 2024

CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire

Oct 03, 2024
pulisher
Sep 30, 2024

GDTCCytoMed Therapeutics Limited Ordinary Shares Latest Stock News & Market Updates - StockTitan

Sep 30, 2024
pulisher
Sep 30, 2024

CYTOMED THERAPEUTICS : AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 6 K - Marketscreener.com

Sep 30, 2024
pulisher
Sep 30, 2024

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire

Sep 30, 2024
pulisher
Sep 30, 2024

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates - Yahoo Finance

Sep 30, 2024
pulisher
Sep 25, 2024

Presenting on the Emerging Growth Conference 75 Day 2 on September 26 - GlobeNewswire

Sep 25, 2024
pulisher
Aug 20, 2024

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewswire

Aug 20, 2024
pulisher
Jul 17, 2024

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewswire

Jul 17, 2024
pulisher
Jun 14, 2024

Emergence of Cell and Gene Therapy Community in Singapore - BSA bureau

Jun 14, 2024
pulisher
Jun 11, 2024

Anti-aging Therapeutics Market Size, Scope, Growth and Forecast to 2031 - InsightAce Analytic

Jun 11, 2024
pulisher
Mar 20, 2024

Navigating the Challenges Facing an Aging Global Population: How CytoMed Seeks to Help Boost Cartilage Regeneration | Value Investing NewsInvestor powered stock market news - Financial Content

Mar 20, 2024
pulisher
Mar 04, 2024

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair - GlobeNewswire

Mar 04, 2024
pulisher
Jan 29, 2024

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Yahoo Finance

Jan 29, 2024
pulisher
Jan 23, 2024

GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView

Jan 23, 2024
pulisher
Dec 05, 2023

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology - PR Newswire

Dec 05, 2023
pulisher
Nov 17, 2023

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update - PR Newswire

Nov 17, 2023
pulisher
Aug 29, 2023

CytoMed Expands Research Collaboration into China After Entering Into MOU - Financial Content

Aug 29, 2023
pulisher
Aug 15, 2023

CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency - PR Newswire

Aug 15, 2023
pulisher
Aug 01, 2023

CytoMed Therapeutics Granted Patent in China for Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Investing.com South Africa

Aug 01, 2023
pulisher
Jul 25, 2023

Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic

Jul 25, 2023

Cytomed Therapeutics Ltd (GDTC) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
大文字化:     |  ボリューム (24 時間):